Immunovant, Inc. (IMVT) stock plummeted 5.10% in the intraday trading session on Monday, following the release of the company's disappointing earnings report for the quarter ended December 31, 2024.
According to the report, Immunovant posted a larger quarterly adjusted loss of $0.76 per share, missing analysts' expectations of a $0.75 loss per share. The company's reported net loss for the quarter widened to $111.12 million, compared to a net loss of $36 million in the same period last year.
Despite reporting zero revenue, in line with expectations, the wider-than-anticipated losses and downward revisions in analysts' earnings estimates seem to have weighed on investor sentiment, driving the stock price lower. However, most analysts maintain a "buy" rating on the stock, with a median 12-month price target of $51.00.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。